瓦克赛特生物
估值 各估值倍数与自身5年区间的对比
同业对比 Biotechnology
| 公司 | 市值 | 市盈率(TTM)i | 市净率i | 股息率i |
|---|---|---|---|---|
| 瓦克赛特生物 (PCVX) | 10.01B | -8.34 | 3.63 | 0.00% |
| Vertex Pharmaceuticals (VRTX) | 126.66B | 29.11 | 6.26 | 0.00% |
| Moderna (MRNA) | 87.04B | -27.32 | 12.87 | 0.00% |
| Regeneron Pharmaceuticals (REGN) | 81.41B | 19.57 | 2.57 | 0.46% |
| argenx SE (ARGX) | 51.51B | 31.21 | 6.12 | 0.00% |
| BeiGene (ONC) | 41.96B | 65.32 | 8.11 | 0.00% |
StockVane 追踪范围内同行业的其他公司。
Morningstar
当前股价高于晨星合理价值估算9.8%。
合理价值
Vaxcyte Inc receives a 3-star quantitative star rating, indicating our belief that this share class is a balanced choice, but prudent investors should consider looking elsewhere. The stock currently trades at a 29% premium over our quantitative fair value estimate of $57.40 per share; however, this estimate should be taken with a pinch of salt due to its very high uncertainty rating. We require the price/fair value ratio to move a certain amount before the star rating can change. This stability-enhancing buffer is in effect for this stock.
The firm's unfavorable dividend structure decreases our fair value estimate. Dividends represent a stable form of future cash flows returned to shareholders, and low dividend payments can increase the perceived risk of a business. Reflecting the firm's dividends is its forward dividend yield of 0%, which ranks in the bottom 30% compared with global peers. This could imply a planned dividend cut or relatively high share price, which contributes to our view that shares are overvalued.
Alternatively, the firm's balance sheet is reassuring. Low leverage mitigates financial risk, potentially boosting a firm's value. The firm's current ratio of 5.7, a core component of leverage, falls in the top 10% compared with global peers. We have little concern about this company's ability to cover near-term obligations, thanks to its relatively high current ratio; this could be a compelling signal during times of distress, which, despite our unfavorable price/fair value ratio, is a positive attribute.
In addition to the aforementioned drivers, our model considers momentum as part of its comprehensive analysis. This share class has outperformed the broader universe over the past year. This outperformance may signify a bull trap, in light of other detractors from our model.
经济护城河
With its quantitative economic moat rating of none, this business is unlikely to consistently outearn its cost of capital without structural protection from competition. However, its financial health score is strong, suggesting that the company should be well positioned to weather tough times.
作者:Quantitative Equity Report
报价时间 2026-10-16 19:30:04 · 仅供参考,不构成投资建议,也未考虑您的具体情况。
瓦克赛特生物 讨论区 0 条评论